# Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta2‐Adrenergic Agonist

**Authors:** Søren Jessen, Andrea Di Credico, Roger Moreno‐Justicia, Lukas Moesgaard, Anders Lemminger, Ben Stocks, Angela Di Baldassarre, Jens Bangsbo, Atul S. Deshmukh, Morten Hostrup

PMC · DOI: 10.1002/jcsm.70175 · Journal of Cachexia, Sarcopenia and Muscle · 2026-01-25

## TL;DR

This study compares how resistance training and beta2-adrenergic stimulation affect muscle proteins, finding shared and unique adaptations that could help treat muscle atrophy.

## Contribution

The study identifies fiber-type-specific proteomic responses to resistance training and beta2-adrenergic stimulation, revealing shared and distinct molecular adaptations.

## Key findings

- Both resistance training and beta2-adrenergic stimulation increased peak power output without significant differences between treatments.
- Resistance training uniquely increased contractile and cytoskeletal proteins, while beta2-adrenergic stimulation affected ribosomal and mitochondrial proteins.
- S100A13 was upregulated in both interventions, while MUSTN1 was regulated only by resistance training.

## Abstract

Skeletal muscle is essential for metabolic health and physical function. While resistance training promotes muscle hypertrophy, alternative therapeutic strategies are needed for individuals unable to engage in physical activity. Because beta2‐adrenergic stimulation induces muscle growth without mechanical load, we assessed muscle fibre type–specific proteomic adaptations to prolonged beta2‐adrenergic stimulation and resistance training to decipher shared and distinct remodelling patterns.

We collected vastus lateralis biopsies from 21 moderately trained young males (mean ± SD, age: 24 ± 3) before and after 4‐week whole‐body resistance training (three sessions/week) or daily inhalation of beta2‐adrenergic agonist terbutaline (4 mg/day). From each biopsy, we isolated 40 muscle fibres and typified them using myosin‐heavy‐chain markers. Fibre pools were analysed using LC–MS/MS‐based proteomics.

Beta2‐adrenergic stimulation and resistance training both increased peak‐power output during bike‐ergometer sprinting (+36 W; 95% CI: 11 to 61, p = 0.007 and +27 W; 95% CI: −1 to 56, p = 0.062, respectively) with no between‐treatments differences (treatment × time interaction: p = 0.644). Beta2‐adrenergic stimulation regulated 15 and 23 proteins in Type I and Type II fibres, respectively, compared to 101 and 65 with resistance training. There was a remarkable fibre type–dependent response, with ~7% of regulated proteins shared between Type I and Type II fibres with resistance training and ~3% with beta2‐adrenergic stimulation. Both interventions increased abundance of ribosomal proteins, in which resistance training induced a 25% increase in Type I fibres (p < 0.001) but only 3% in Type II (p = 0.374), while beta2‐adrenergic stimulation increased ribosomal proteins in both fibre types (Type I: 6% increase, p = 0.008; Type II: 9% increase, p < 0.001). Mitochondrial electron‐transport‐chain protein abundances decreased with both interventions: resistance training reduced abundances mainly in Type I fibres (17% decrease, p < 0.001; Type II: 5% decrease, p = 0.147), while beta2‐adrenergic stimulation caused uniform decreases (Type I: 7% decrease, p = 0.018; Type II: 9% decrease, p = 0.001). Resistance training uniquely increased contractile, cytoskeletal and extracellular matrix proteins, which was not mimicked by beta2‐adrenergic stimulation. S100A13 was upregulated across both interventions and fibre types, whereas MUSTN1 was regulated exclusively with resistance training. Knock‐down of S100a13 (−52%; p < 0.001) and Mustn1 (−96%; p < 0.001) in C2C12 myotubes impaired myotube formation (fusion index: S100a13: −5%; p = 0.002; Mustn1: −21%; p < 0.001).

Beta2‐adrenergic stimulation induces proteomic adaptations that partially mimic resistance training, particularly in ribosomal proteins. Shared regulation of S100A13 and unique regulation of MUSTN1 with resistance training suggest distinct and complementary roles in regulating muscle growth. These findings indicate that the beta2‐adrenergic receptor is a potential target to counter muscle atrophic conditions, offering a pharmacological approach for individuals unable to engage in resistance training.

## Linked entities

- **Genes:** S100A13 (S100 calcium binding protein A13) [NCBI Gene 6284], MUSTN1 (musculoskeletal, embryonic nuclear protein 1) [NCBI Gene 389125], S100A13 (S100 calcium binding protein A13) [NCBI Gene 6284], MUSTN1 (musculoskeletal, embryonic nuclear protein 1) [NCBI Gene 389125]
- **Proteins:** S100A13 (S100 calcium binding protein A13), MUSTN1 (musculoskeletal, embryonic nuclear protein 1)
- **Chemicals:** terbutaline (PubChem CID 5403)

## Full-text entities

- **Genes:** Mustn1 (musculoskeletal, embryonic nuclear protein 1) [NCBI Gene 66175] {aka 1110028G01Rik, Mustang}, MYH7 (myosin heavy chain 7) [NCBI Gene 4625] {aka CMD1S, CMH1, CMYO7A, CMYO7B, CMYP7A, CMYP7B}, MYBPH (myosin binding protein H) [NCBI Gene 4608], FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, LMOD2 (leiomodin 2) [NCBI Gene 442721] {aka C-LMOD, CLMOD, CMD2G}, LMOD3 (leiomodin 3) [NCBI Gene 56203] {aka NEM10}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, Fgf1 (fibroblast growth factor 1) [NCBI Gene 14164] {aka Dffrx, Fam, Fgf-1, Fgf2b, Fgfa}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, EZR (ezrin) [NCBI Gene 7430] {aka CVIL, CVL, HEL-S-105, VIL2}, FBN1 (fibrillin 1) [NCBI Gene 2200] {aka ACMICD, ECTOL1, FBN, GPHYSD2, MASS, MFLS}, MYL2 (myosin light chain 2) [NCBI Gene 4633] {aka CMH10, MFM12, MLC-2, MLC-2s/v, MLC-2v, MLC2}, MYH6 (myosin heavy chain 6) [NCBI Gene 4624] {aka ASD3, CMD1EE, CMH14, MYHC, MYHCA, SSS3}, Myh7 (myosin, heavy polypeptide 7, cardiac muscle, beta) [NCBI Gene 140781] {aka B-MHC, MYH-beta/slow, MyHC-I, Myhc-b, Myhcb, beta-MHC}, S100A13 (S100 calcium binding protein A13) [NCBI Gene 6284], MYH1 (myosin heavy chain 1) [NCBI Gene 4619] {aka HEL71, MYHSA1, MYHa, MyHC-2X/D, MyHC-2x}, TNNC1 (troponin C1, slow skeletal and cardiac type) [NCBI Gene 7134] {aka CMD1Z, CMH13, TN-C, TNC, TNNC}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, ATP2B1 (ATPase plasma membrane Ca2+ transporting 1) [NCBI Gene 490] {aka MRD66, PMCA1, PMCA1kb}, ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, FLII (FLII actin remodeling protein) [NCBI Gene 2314] {aka CMD2J, FLI, FLIL, Fli1}, Myh2 (myosin, heavy polypeptide 2, skeletal muscle, adult) [NCBI Gene 17882] {aka MHC2A, MyHC-2a, MyHC-IIa, Myh2a, Myhs-f, Myhs-f1}, MYH2 (myosin heavy chain 2) [NCBI Gene 4620] {aka CMYO6, CMYP6, IBM3, MYH2A, MYHSA2, MYHas8}, MUTYH (mutY DNA glycosylase) [NCBI Gene 4595] {aka MYH}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, MUSTN1 (musculoskeletal, embryonic nuclear protein 1) [NCBI Gene 389125] {aka MUSTANG}, FBLN5 (fibulin 5) [NCBI Gene 10516] {aka ADCL2, ARCL1A, ARMD3, CMT1H, DANCE, EVEC}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, MYL3 (myosin light chain 3) [NCBI Gene 4634] {aka CMH8, MLC-lV/sb, MLC1SB, MLC1V, VLC1, VLCl}, RPL35 (ribosomal protein L35) [NCBI Gene 11224] {aka DBA19, L35, uL29}, TNNI1 (troponin I1, slow skeletal type) [NCBI Gene 7135] {aka SSTNI, TNN1}, IGKV5-2 (immunoglobulin kappa variable 5-2) [NCBI Gene 28907] {aka B2, IGKV52}, S100a13 (S100 calcium binding protein A13) [NCBI Gene 20196]
- **Diseases:** asthma (MESH:D001249), muscle atrophy (MESH:D009133), loss of muscle mass, function (MESH:D009135), cachexia (MESH:D002100), ID (MESH:C537985), tumour (MESH:D009369), sarcopenia (MESH:D055948), atrophic conditions (MESH:D020966), obese (MESH:D009765), hypertrophic (MESH:D002312), hypertrophy (MESH:D006984), Muscle Hypertrophy (MESH:C536106), quality of life (MESH:D003643), muscle (MESH:D019042), insulin resistance (MESH:D007333)
- **Chemicals:** acetonitrile (MESH:C032159), isopropanol (MESH:D019840), Alex Fluor 546 (-), Alexa Fluor 546 (MESH:C481052), glucose (MESH:D005947), DAPI (MESH:C007293), nitrogen (MESH:D009584), TFA (MESH:D014269), sodium dodecyl sulphate (MESH:D012967), lipid (MESH:D008055), epinephrine (MESH:D004837), calcium (MESH:D002118), TEAB (MESH:C041737), fatty acid (MESH:D005227), lidocaine (MESH:D008012), NaCl (MESH:D012965), CAA (MESH:C013874), water (MESH:D014867), SYBR Green (MESH:C098022), FA (MESH:D005492), Terbutaline (MESH:D013726), DTT (MESH:D004229), Lipofectamine (MESH:C086724), PBS (MESH:D007854), CO2 (MESH:D002245), TCA (MESH:D014233), PVDF (MESH:C024865), acids (MESH:D000143), O2 (MESH:D010100), carbohydrates (MESH:D002241), streptomycin (MESH:D013307), ethanol (MESH:D000431), paraformaldehyde (MESH:C003043), Triton-X 100 (MESH:D017830), penicillin (MESH:D010406), Tween-20 (MESH:D011136)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833500/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833500/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833500/full.md

---
Source: https://tomesphere.com/paper/PMC12833500